Venus Concept to Release First Quarter of Fiscal Year 2023 Financial Results on May 15, 2023
Venus Concept (NASDAQ: VERO) announced its first quarter fiscal year 2023 financial results will be released on May 15, 2023, before market opening. The management will host a conference call at 8:00 a.m. Eastern Time the same day to discuss these results, with a Q&A session to follow. Participants can join via phone or listen to a live webcast on the investor relations section of the Company's website.
Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products across 60 countries. Their extensive product lineup includes devices for aesthetic treatments and hair restoration, supported by notable healthcare industry investors.
- Scheduled financial results release on May 15, 2023.
- Live conference call with management for transparent communication.
- Broad product portfolio in a growing global market.
- None.
TORONTO, April 11, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2023 financial results will be released before the market opens on Monday, May 15, 2023.
Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2023 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13737854. A live webcast of the call will also be provided on the investor relations section of the Company's website at ir.venusconcept.com.
For those unable to participate, a replay of the call will be available for two weeks at: 877-660-6853 (201-612-7415 for international callers); access code 13737854. The webcast will be archived at ir.venusconcept.com.
About Venus Concept
Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 15 direct markets. Venus Concept’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept’s hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.
FAQ
When will Venus Concept release its Q1 2023 financial results?
What time is the conference call for Venus Concept's Q1 earnings?
How can I listen to the Venus Concept earnings call?
